AXSM SEC Filing News — Axsome Therapeutics, Inc.

Latest SEC filings for Axsome Therapeutics, Inc. (AXSM) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-03.

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptak…
Sector: Healthcare Industry: Biotechnology Market Cap: $8.2B
20
Total Filings
0
Bullish Classifications
9
Bearish Classifications
8
Insider Transactions
2
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for AXSM currently lean bearish. Of the 20 filing records displayed, 9 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
AXSM Filing Activity Snapshot 2026-06-09 — 2026-09-03
Insider Transactions (Form 4)
0 buys vs 6 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$12.20M
Herriot Tabuteau · 2026-06-09
49,670 shares · Form 144
Form 144 Notices
9
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 8 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 8 filings in this group are Form 4s for Axsome Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 8 insider filings shown, the breakdown is 6 open-market sale and 2 option exercise. 6 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×6
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Option exercise ×2
The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Form 4 Open-market sale Insider Selling 2026-09-03

AXSM insider Jacobson Mark L. (Chief Operating Officer) sold 10,000 shares (~$2.09M)

Jacobson Mark L., listed as Chief Operating Officer at Axsome Therapeutics, Inc., reported an open-market sale of 10,000 AXSM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 10,000 $12.95 $129.5K
S Open-market sale 10,000 $208.65 $2.09M
M Option exercise derivative · Stock Option (Right to Buy) 10,000 — —
Filing: Form 4 (Insider Transaction) Insider: Jacobson Mark L. (Chief Operating Officer) Shares: 10,000 Est. Value: $2.09M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-08-07

AXSM insider TABUTEAU HERRIOT (Director, Chief Executive Officer, 10% Owner) sold 49,664 shares (~$10.54M)

TABUTEAU HERRIOT, listed as Director, Chief Executive Officer, 10% Owner at Axsome Therapeutics, Inc., reported an open-market sale of 49,664 AXSM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 45,004 $4.95 $222.8K
S Open-market sale 45,004 $212.01 $9.54M
M Option exercise 4,660 $4.95 $23.1K
S Open-market sale 4,660 $213.95 $997.0K
M Option exercise derivative · Stock Option (Right to Buy) 45,004 — —
M Option exercise derivative · Stock Option (Right to Buy) 4,660 — —
Filing: Form 4 (Insider Transaction) Insider: TABUTEAU HERRIOT (Director, Chief Executive Officer, 10% Owner) Shares: 49,664 Est. Value: $10.54M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-01

AXSM insider TABUTEAU HERRIOT (Director, Chief Executive Officer, 10% Owner) sold 49,666 shares (~$11.93M)

TABUTEAU HERRIOT, listed as Director, Chief Executive Officer, 10% Owner at Axsome Therapeutics, Inc., reported an open-market sale of 49,666 AXSM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 49,666 $4.95 $245.8K
S Open-market sale 49,666 $240.25 $11.93M
M Option exercise derivative · Stock Option (Right to Buy) 49,666 — —
Filing: Form 4 (Insider Transaction) Insider: TABUTEAU HERRIOT (Director, Chief Executive Officer, 10% Owner) Shares: 49,666 Est. Value: $11.93M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-11

AXSM insider JEFFS ROGER (Director) sold 572 shares (~$141.7K)

JEFFS ROGER, listed as Director at Axsome Therapeutics, Inc., reported an open-market sale of 572 AXSM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 286 $246.18 $70.4K
S Open-market sale 286 $249.12 $71.2K
Filing: Form 4 (Insider Transaction) Insider: JEFFS ROGER (Director) Shares: 572 Est. Value: $141.7K
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-06-10

AXSM insider Form 4 filed for equity award, exercise, or tax withholding

JEFFS ROGER (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 1,429 — —
M Option exercise derivative · Restricted Stock Units 1,429 — —
Filing: Form 4 (Insider Transaction) Insider: JEFFS ROGER (Director) Shares: 1,429
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-06-10

AXSM insider Form 4 filed for equity award, exercise, or tax withholding

Saad Mark E (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 1,429 — —
M Option exercise derivative · Restricted Stock Units 1,429 — —
Filing: Form 4 (Insider Transaction) Insider: Saad Mark E (Director) Shares: 1,429
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-10

AXSM insider Mahony Susan (Director) sold 600 shares (~$145.0K)

Mahony Susan, listed as Director at Axsome Therapeutics, Inc., reported an open-market sale of 600 AXSM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 1,429 — —
S Open-market sale 300 $237.21 $71.2K
S Open-market sale 300 $246.18 $73.9K
M Option exercise derivative · Restricted Stock Units 1,429 — —
Filing: Form 4 (Insider Transaction) Insider: Mahony Susan (Director) Shares: 600 Est. Value: $145.0K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-10

AXSM insider Coleman Mark (Director) sold 643 shares (~$160.1K)

Coleman Mark, listed as Director at Axsome Therapeutics, Inc., reported an open-market sale of 643 AXSM shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 1,429 — —
S Open-market sale 643 $249.00 $160.1K
M Option exercise derivative · Restricted Stock Units 1,429 — —
Filing: Form 4 (Insider Transaction) Insider: Coleman Mark (Director) Shares: 643 Est. Value: $160.1K
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 9 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Axsome Therapeutics, Inc. has 9 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-03

AXSM Form 144 filed for proposed insider sale by Mark Jacobson (10,000 shares) ~$2.08M

Mark Jacobson filed a Form 144 with the SEC indicating intent to sell AXSM (Axsome Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Mark Jacobson Shares: 10,000 Est. Value: $2.08M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-08-06

AXSM Form 144 filed for proposed insider sale by Herriot Tabuteau (4,660 shares) ~$979.2K

Herriot Tabuteau filed a Form 144 with the SEC indicating intent to sell AXSM (Axsome Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Herriot Tabuteau Shares: 4,660 Est. Value: $979.2K
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-08-05

AXSM Form 144 filed for proposed insider sale by Herriot Tabuteau (45,004 shares) ~$9.58M

Herriot Tabuteau filed a Form 144 with the SEC indicating intent to sell AXSM (Axsome Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Herriot Tabuteau Shares: 45,004 Est. Value: $9.58M
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-07-01

AXSM Form 144 filed for proposed insider sale by Herriot Tabuteau (49,666 shares) ~$11.95M

Herriot Tabuteau filed a Form 144 with the SEC indicating intent to sell AXSM (Axsome Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Herriot Tabuteau Shares: 49,666 Est. Value: $11.95M
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-11

AXSM Form 144 filed for proposed insider sale by JEFFS ROGER (286 shares) ~$71.2K

JEFFS ROGER filed a Form 144 with the SEC indicating intent to sell AXSM (Axsome Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: JEFFS ROGER Shares: 286 Est. Value: $71.2K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-10

AXSM Form 144 filed for proposed insider sale by Mahony Susan (300 shares) ~$73.9K

Mahony Susan filed a Form 144 with the SEC indicating intent to sell AXSM (Axsome Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Mahony Susan Shares: 300 Est. Value: $73.9K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-10

AXSM Form 144 filed for proposed insider sale by JEFFS ROGER (286 shares) ~$70.4K

JEFFS ROGER filed a Form 144 with the SEC indicating intent to sell AXSM (Axsome Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: JEFFS ROGER Shares: 286 Est. Value: $70.4K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-10

AXSM Form 144 filed for proposed insider sale by Coleman Mark (643 shares) ~$160.1K

Coleman Mark filed a Form 144 with the SEC indicating intent to sell AXSM (Axsome Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Coleman Mark Shares: 643 Est. Value: $160.1K
View on SEC EDGAR → Open Filing Document →
Form 144 Large Proposed Insider Sale 2026-06-09

AXSM Form 144 filed for proposed insider sale by Herriot Tabuteau (49,670 shares) ~$12.20M

Herriot Tabuteau filed a Form 144 with the SEC indicating intent to sell AXSM (Axsome Therapeutics, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: Herriot Tabuteau Shares: 49,670 Est. Value: $12.20M
View on SEC EDGAR → Open Filing Document →
Material Events 2 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 2 in this period for Axsome Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-10

AXSM filed 8-K — material company event

Axsome Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Form 8-K Material Company Update 2026-07-15

AXSM filed 8-K — material company event

Axsome Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Axsome Therapeutics, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-10

AXSM filed Quarterly Report (10-Q)

Axsome Therapeutics, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify Axsome Therapeutics, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on AXSM. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — AXSM SEC Filings

More Tools for AXSM

AXSM Full Stock Analysis AXSM Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper AXSM analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the AXSM stock analysis page.

AXSM Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer